Lung cancer and pancreatic cancer account for the highest and 4th highest annual cancer deaths in the United States, respectively. In fact, pancreatic cancer is expected to become the 2nd most lethal cancer by 2030. Due to advances in screening, treatment and increased smoking cessation, the annual death rate for lung cancer in the U.S. has fallen from 60 per 100,000 persons in 1992 to under 40 by 2017. However, pancreatic cancer presents a grimmer story. From 1992 to 2017, the annual death rate for pancreatic cancer has remained steady at about 11 per 100,000 persons.
Although we should celebrate the advancements that have been made, both of these cancer indications remain difficult to detect early and treat. Therefore, Skipper Bio Med works with our clients to develop a coordinated strategy and facilitate proactive engagement with the right key opinion leaders (clinical, regulatory, etc) to ensure that more research innovations can become available to patients and ultimately improve their outcomes.